Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. by Robert, C, Dummer, R, Gutzmer, R, Lorigan, P, Kim, K, Nyakas, M, Arance, A, Liszkay, G, Schadendorf, D, Cantarini, M, Spencer, S, Middleton, MR

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: A phase 2 double-blind randomised study by Robert, C, Dummer, R, Gutzmer, R, Lorigan, P, Kim, K, Nyakas, M, Arance, A, Liszkay, G, Schadendorf, D, Cantarini, M, Spencer, S, Middleton, MR

Improved survival with MEK inhibition in BRAF-mutated melanoma. by Flaherty, K, Robert, C, Hersey, P, Nathan, P, Garbe, C, Milhem, M, Demidov, L, Hassel, J, Rutkowski, P, Mohr, P, Dummer, R, Trefzer, U, Larkin, J, Utikal, J, Dreno, B, Nyakas, M, Middleton, M, Becker, J, Casey, M, Sherman, L, Wu, F, Ouellet, D, Martin, A, Patel, K, Schadendorf, D